Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

Next Previous
X
Search
Trial Profile

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir alafenamide (Primary)
  • Indications Fatigue; Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 28 Aug 2022 Status changed from not yet recruiting to suspended due to funding.
    • 20 Oct 2021 Planned End Date changed from 14 Feb 2024 to 14 Feb 2025.
    • 20 Oct 2021 Planned primary completion date changed from 14 Feb 2023 to 14 Feb 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top